Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human EPH Receptor A2 Anticorps:
anti-Rat (Rattus) EPH Receptor A2 Anticorps:
anti-Mouse (Murine) EPH Receptor A2 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal EPH Receptor A2 Primary Antibody pour CyTOF, FACS - ABIN4899913
Gopal, Bohonowych, Lema-Tome, Liu, Garrett-Mayer, Wang, Isaacs: A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. dans PLoS ONE 2011
Show all 4 Pubmed References
Human Monoclonal EPH Receptor A2 Primary Antibody pour CyTOF, FACS - ABIN4899912
Liao-Chan, Daine-Matsuoka, Heald, Wong, Lin, Cai, Lai, DAlessio, Theunissen: Quantitative assessment of antibody internalization with novel monoclonal antibodies against Alexa fluorophores. dans PLoS ONE 2015
Show all 4 Pubmed References
Mouse (Murine) Monoclonal EPH Receptor A2 Primary Antibody pour CyTOF, FACS - ABIN4899679
De Robertis, Loiacono, Fusilli, Poeta, Mazza, Sanchez, Marchionni, Signori, Lamorte, Vescovi, Garcia-Foncillas, Fazio: Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. dans Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Show all 3 Pubmed References
Human Monoclonal EPH Receptor A2 Primary Antibody pour IHC, ELISA - ABIN1724651
Landen, Kinch, Sood: EphA2 as a target for ovarian cancer therapy. dans Expert opinion on therapeutic targets 2005
Show all 2 Pubmed References
Human Polyclonal EPH Receptor A2 Primary Antibody pour IF (p), IHC (p) - ABIN669201
Wu, Fu, Zhou, Gong, Liu, Qiao, Li: HIF-1? and HIF-2?: siblings in promoting angiogenesis of residual hepatocellular carcinoma after high-intensity focused ultrasound ablation. dans PLoS ONE 2014
Human Monoclonal EPH Receptor A2 Primary Antibody pour IHC, ELISA - ABIN966072
Abraham, Knapp, Cheng, Snyder, Mittal, Bangari, Kinch, Wu, Dhariwal, Mohammed: Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. dans Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Show all 2 Pubmed References
Human Monoclonal EPH Receptor A2 Primary Antibody pour FACS - ABIN4896889
Udyavar, Wooten, Hoeksema, Bansal, Califano, Estrada, Schnell, Irish, Massion, Quaranta: Novel Hybrid Phenotype Revealed in Small Cell Lung Cancer by a Transcription Factor Network Model That Can Explain Tumor Heterogeneity. dans Cancer research 2017
Human Monoclonal EPH Receptor A2 Primary Antibody pour FACS - ABIN4896891
Haas, Sciuto, Brunetto, Valvo, Signore, Fiori, di Martino, Giannetti, Morgante, Boe, Patrizii, Warnken, Schnölzer, Ciolfi, Di Stefano, Biffoni, Ricci-Vitiani, Pallini, De Maria: Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. dans Cell stem cell 2017
findings suggested inhibition of HDACs-EphA2 signaling axis with WW437 alone or in combination with other agents may be a promising therapeutic strategy for advanced breast cancer.
High EPHA2 expression is associated with epithelial-mesenchymal transition in gastric cancer.
Ligand-independent activation of EphA2 was triggered by VEGF (Montrer VEGFA Anticorps) released from CAF (Montrer KAT2B Anticorps)-CM.
EphA2-mediates glutaminolysis through YAP (Montrer YAP1 Anticorps)/TAZ (Montrer TAZ Anticorps) activation in HER2 (Montrer ERBB2 Anticorps)-positive breast cancer and may serve as potential therapeutic targets in patients.
Data indicate a promising role for EPH receptor A2 (EPHA2) as a target in antibody treatments for melanoma.
These observations demonstrate that EphA2 affects the sensitivity to oxaliplatin by inducing EMT (Montrer ITK Anticorps) in oxaliplatin-resistant gastric cancer cells.
High erythropoietin (Montrer EPO Anticorps)-producing hepatocellular carcinoma receptor A (EphA) 1 (Montrer EPHA1 Anticorps), 2, and 4 expression levels were significantly related to recurrence.
Data show that Ephrin B3 (Montrer EFNB3 Anticorps) was concomitantly expressed with EphA2 and Ephrin A1 (Montrer EFNA1 Anticorps) with higher Ephrin B3 (Montrer EFNB3 Anticorps) levels found in non-squamous than in squamous tumors.
These results suggest that EphA2/Efna1/Egfr genes, linked to a possible control by miR-200a and miR-26b, could be proposed as novel CRC prognostic biomarkers. Moreover, EphA2 could be linked to a mechanism of resistance to cetuximab alternative to KRAS mutations.
the dimer structures of human EphA2 receptor depend on the lipid environment, which we show is linked to the location of the structural motifs in the dimer interface, thereby establishing that both sequence and membrane composition modulate the complete energy landscape of membrane-bound proteins.
The present study successfully assessed the expression pattern of miR26b in the pituitary tissue of Yanbian cattle, and also confirmed that EphA2 was a target gene of miR26b in Yanbian cattle in vitro.
Collectively, these data suggest that ATRA attenuates bleomycin-induced pulmonary fibrosis by regulating EphA2-EphrinA1 and PI3K-Akt (Montrer AKT1 Anticorps) signaling.
Lipopolysaccharide exposure significantly up-regulated EphA2 and EphrinA1 expression.
modulation of EphA2 signaling might contribute to effective transplantation of tissue-specific resident macrophages and/or monocytes
Our data suggest that EphA2 is closely related to the formation of osteoblasts and resorption of osteoclast and is likely to play an role in bone resorption induced in chronic periodontitis
We examined the roles of ephrin-A2 (Montrer EFNA2 Anticorps) and ephrin-A5 (Montrer EFNA5 Anticorps) signaling in contralateral targeting and topographic ordering in the ventral cochlear nucleus
EphA2 acts as a KRas cooperative tumor suppressor
Data shows that modulation of angiostatic factor Slit2 (Montrer SLIT2 Anticorps) by EphA2 receptor regulates endothelial responses to VEGF (Montrer VEGFA Anticorps)-mediated angiogenesis and tumor neovascularization.
Sporozoites productively infected hepatocytes with high EphA2 expression, and the deletion of EphA2 protected mice from liver infection.
EphA2-mutant mice are more prone to hyperglycemia-induced increased injury and decreased survival.
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders.
ephrin type-A receptor 2
, epithelial cell receptor protein tyrosine kinase
, soluble EPHA2 variant 1
, tyrosine-protein kinase receptor ECK
, ephrin receptor EphA2
, epoxide hydrolase
, EPH receptor A2
, epithelial cell kinase
, tyrosine-protein kinase receptor MPK-5
, tyrosine-protein kinase receptor SEK-2
, protein tyrosine kinase EphA2
, eph-like receptor tyrosine kinase 6
, EPH receptor A2 L homeolog
, ephrin receptor EphA2 (tyrosine kinase family)